Rahman, Mahfuzur https://orcid.org/0000-0002-9226-3988
Billmann, Maximilian https://orcid.org/0000-0002-6556-9594
Costanzo, Michael https://orcid.org/0000-0002-7906-2604
Aregger, Michael https://orcid.org/0000-0001-6443-9870
Tong, Amy H Y
Chan, Katherine
Ward, Henry N https://orcid.org/0000-0002-9869-9790
Brown, Kevin R https://orcid.org/0000-0002-5514-2538
Andrews, Brenda J https://orcid.org/0000-0001-6427-6493
Boone, Charles https://orcid.org/0000-0002-3542-6760
Moffat, Jason https://orcid.org/0000-0002-5663-8586
Myers, Chad L https://orcid.org/0000-0002-1026-5972
Funding for this research was provided by:
National Science Foundation (MCB 1818293)
HHS|National Institutes of Health (R01HG005084)
HHS|National Institutes of Health (R01HG005853)
Gouvernement du Canada|Canadian Institutes of Health Research (MOP‐142375)
Deutsche Forschungsgemeinschaft (Bi2086/1‐1)
Ontario Research Foundation
Article History
Received: 22 September 2020
Revised: 19 April 2021
Accepted: 20 April 2021
First Online: 20 May 2021
Conflict of interest
: J.M. is a shareholder in Northern Biologics and Pionyr Immunotherapeutics, and is an advisor and shareholder of Century Therapeutics and Aelian Biotechnology. The authors declare no conflict of interest.